Evidence map›Paper›PMID 30367192›Full record

ArticleExperimental brain research2019

Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.

Lillian M Toomey, Carole A Bartlett, Maimuna Majimbi, Gopana Gopalasingam, Jennifer Rodger, Melinda Fitzgerald

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Experimental brain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lillian M ToomeyExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia.
Carole A BartlettExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia.
Maimuna MajimbiCurtin Health Innovation Research Institute, Curtin University, Bentley, Australia.
Gopana GopalasingamExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia.
Jennifer RodgerExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia.
Melinda FitzgeraldExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia. lindy.fitzgerald@curtin.edu.au.ORCID http://orcid.org/0000-0002-4823-8179
The University of Western Australia · AUCurtin University · AU

Funding

National Health and Medical Research Council APP1087114
6 · The paper itself

Abstract

Following neurotrauma, secondary degeneration of neurons and glia adjacent to the injury leads to further functional loss. A combination of ion channel inhibitors (lomerizine + oxATP + YM872) has been shown to be effective at limiting structural and functional loss due to secondary degeneration. Here we assess efficacy of the combination where oxATP is replaced with Brilliant Blue G (BBG), a more clinically applicable P2X

Indexed as

AnimalsCalcium-Binding ProteinsCalcium Channel BlockersCell Adhesion Molecules, NeuronalDisease Models, AnimalDrug Delivery SystemsDrug Therapy, CombinationEctodysplasinsFemaleImidazolesIon ChannelsMacrophagesMicrofilament ProteinsMicrogliaNerve DegenerationNystagmus, OptokineticAif1 protein, ratCalcium-Binding ProteinsCalcium Channel BlockersCell Adhesion Molecules, NeuronalCntnap1 protein, ratcoomassie Brilliant BlueEctodysplasinsImidazolesIon ChannelslomerizineMicrofilament ProteinsOligodendrocyte Transcription Factor 2PiperazinesQuinoxalinesReceptor, Platelet-Derived Growth Factor alphaRosaniline DyesTubulinYM 872Ion channel inhibitorMyelinNeurotraumaSecondary degenerationVisual function

Identifiers

PMID30367192
OpenAlexW2898321188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.